Valeant's Many Acquisitions Led to Manufacturing Issues, Says the FDA

As if Joe Papa doesn’t have enough problems.

The Valeant Pharmaceuticals chief executive is grappling with numerous government probes into the company’s accounting and pricing practices; its business strategy is in turmoil; assets are being sold to ward off bondholders and its stock is tanking, again.

Now, the US Food and Drug Administration has sent a warning letter that notes the company is having manufacturing problems that reflect an inability to integrate some of the products that have been scooped up as a result of its many acquisitions.

Back to news